biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > and i am sure chrispi will find this to be very positive

<< Previous

Bullboard Posts

Next >>

Comment by chrispion Jun 20, 2022 7:29pm

180 Views

Post# 34769986

RE:and i am sure chrispi will find this to be very positive

chrispi probably views this pivot as incredibly positive. lol
it's scary how cluless you appear to be

The webinar was to discuss the acquired EGF assets not about what is coming in the next months on xB3 programs and partnerships.
I'm reminded of a great radio show by Paul Harvey ... and now The Rest of the Story

Stay tuned FRT and his lapdogs ... you'll understand why I'm reminded of that show :)

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario